Daclaxen 60 mg Tablets
Daclaxen 60 mg Tablets is a trusted medication containing Daclatasvir, designed for personal use under the guidance of a healthcare professional. Available for prescription-based international supply with discreet worldwide delivery.
- Active ingredient: Daclatasvir
- Strength: 60 mg
- Form: Tablet
- Indication: Chronic Hepatitis C (genotypes 1, 3, 4)
- Manufacturer: Everest Pharmaceuticals Ltd.
Select quantity:
What is Daclatasvir?
How Does It Work?
Daclatasvir binds to domain I of the HCV NS5A protein, disrupting its role in viral RNA replication and assembly.
NS5A is essential for organising the membranous web where HCV replication occurs. Daclatasvir prevents the formation of functional replication complexes.
In addition to blocking replication, NS5A inhibitors including daclatasvir impair the assembly and secretion of new HCV particles.
How to Use
Take exactly as prescribed. Your prescriber's instructions replace the general guidance above.
Side Effects & Precautions
- Headache
- Fatigue
- Nausea
- Diarrhoea
- Serious symptomatic bradycardia when co-administered with amiodarone (class effect with sofosbuvir combination)
- Hepatitis B reactivation in HBV/HCV co-infected patients
- Elevated liver enzymes
- Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John's Wort)
- Known hypersensitivity to daclatasvir
Generic vs Brand
Simran Jha is a licensed clinical pharmacist with 17 years of experience. She holds a B.Pharm and M.Pharm from Dr. YSR University of Health Sciences. At OnlineMeds, she reviews medicine and health content to help ensure it is accurate, evidence-based, and easy to understand.
Storage & Handling
Why Buy From Us
Sourced directly from licensed pharmaceutical manufacturers.
Sourced from licensed manufacturers through regulated supply channels.
Discreet shipping to UK, US, AU, EU and beyond.
Regulated and compliant with international pharmacy standards.
Frequently Asked Questions
Test all patients for current or prior HBV infection before initiating daclatasvir. HBV reactivation has been reported during or after HCV treatment and may result in fulminant hepatitis or death.
Drug Interactions
| Drug / Substance | Effect | Action |
|---|---|---|
| Strong CYP3A4 inducers (rifampicin) | Dramatically reduces daclatasvir exposure | Contraindicated |
| Strong CYP3A4 inhibitors (clarithromycin) | Increases daclatasvir exposure — adjust dose to 30mg | Reduce daclatasvir dose to 30mg once daily |
| Atazanavir (HIV protease inhibitor) | Increases daclatasvir exposure significantly | Reduce daclatasvir dose to 30mg once daily |
Approved Indications
- Chronic HCV genotype 1 (with sofosbuvir) FDA / EMA
- Chronic HCV genotype 3 (with sofosbuvir) EMA (WHO-recommended)
- Chronic HCV genotype 4 (with sofosbuvir) EMA